John Libbey Eurotext

Cahiers Santé Médecine Thérapeutique

MENU

Janus kinases inhibitors Volume 31, issue 2, mars-avril 2022

Figures


  • Figure 1

  • Figure 2

Tables

Authors
Hôpital militaire Moulay-Ismail, Meknes, Maroc
* Tirés à part : E. Boudhar

Therapeutic advances in inflammatory diseases go hand in hand with deciphering the pathophysiology of autoimmune and inflammatory diseases. It is now recognised that intracellular components of cytokine signalling, in particular the signal transducing Janus kinase (JAK) family, can be targeted to inhibit the effect of a wide range of cytokines. JAKs are intracytoplasmic protein tyrosine kinases that bind to the cytoplasmic region of cytokine transmembrane receptors and mediate signalling via type 1 and type 2 cytokine receptors. JAK inhibitors (JAKIs) can be divided into two classes: first-generation non-selective pan-JAKIs and next-generation selective JAKIs. There are now several FDA/EMA licensed JAK inhibitors for the treatment of inflammatory and autoimmune diseases, and others are currently in clinical trials. The results of these studies are eagerly awaited as they may broaden the use of JAK inhibitors and may change treatment paradigms with rapid dose-dependent action and fewer side effects, and possibly also as monotherapy. Here we provide a synthetic and systematic review of JAK inhibitors.